Publications by authors named "J E Brunetti"
Article Synopsis
- Immunogenic cell death (ICD) offers a new avenue for treating non-immunoreactive tumors that typically resist standard therapies.
- The study focused on two new oncolytic peptides, BOP7 and BOP9, which selectively killed pancreatic cancer cells while sparing non-tumor cells, attributed to their ability to bind to specific molecules on cancer cells.
- BOPs not only showed promising tumor-specific cytotoxicity, triggering the release of pro-inflammatory signals (DAMPs), but also demonstrated anti-metastatic properties and effectiveness in reducing tumor growth in a mouse model of pancreatic cancer.
Article Synopsis
- * A selection of six branched peptides, designed to improve resistance to proteases and boost efficacy, was tested for antibacterial activity, biofilm inhibition, cytotoxicity, and resistance to breakdown.
- * The peptide BAMP2 demonstrated encouraging results in treating mouse skin infections, suggesting its potential for local application in infection management.
Store-operated Ca entry (SOCE) mediated by stromal interacting molecule (STIM)-gated ORAI channels at endoplasmic reticulum (ER) and plasma membrane (PM) contact sites maintains adequate levels of Ca within the ER lumen during Ca signaling. Disruption of ER Ca homeostasis activates the unfolded protein response (UPR) to restore proteostasis. Here, we report that the UPR transducer inositol-requiring enzyme 1 (IRE1) interacts with STIM1, promotes ER-PM contact sites, and enhances SOCE.
View Article and Find Full Text PDFBackground: Loss of function mutations in PCDH19 gene causes an X-linked, infant-onset clustering epilepsy, associated with intellectual disability and autistic features. The unique pattern of inheritance includes random X-chromosome inactivation, which leads to pathological tissue mosaicism. Females carrying PCDH19 mutations are affected, while males have a normal phenotype.
View Article and Find Full Text PDFSET-M33 is a synthetic peptide that is being developed as a new antibiotic against major Gram-negative bacteria. Here we report two in vivo studies to assess the toxicity and efficacy of the peptide in a murine model of pulmonary inflammation. First, we present the toxicity study in which SET-M33 was administered to CD-1 mice by snout inhalation exposure for 1 h/day for 7 days at doses of 5 and 20 mg/kg/day.
View Article and Find Full Text PDF